The EPS miss is significant but partly driven by one-time milestone charges. Watch for the AET ANDA litigation ruling expected around February 2027, which could impact WAKIX exclusivity. The BP-205 Phase 1b data in Q1 2027 is a key pipeline catalyst.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 4 $34.42entry
- T+1 · 12d ago −5.65%α −1.24% · $32.47
- T+5 · 6d ago −0.57%α +0.35% · $34.22
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Harmony Biosciences reported Q3 2026 WAKIX net revenue of $268.9M (+12% YoY), slightly below the $272.1M consensus. GAAP diluted EPS of $0.81 missed the $1.47 consensus, driven by a $25M milestone charge and higher royalties. The company reiterated full-year revenue guidance of $1.0B-$1.04B and highlighted positive early BP-205 MAD study data.
Key Financial Metrics
Key Facts
- Q3 2026 WAKIX net revenue $268.9M, +12% YoY from $239.5M, vs consensus $272.1M
- GAAP diluted EPS $0.81, down from $0.87 YoY, vs consensus $1.47
- Net income $48.2M vs $50.9M YoY; operating income $54.2M vs $65.5M YoY
- Cost of product sold rose to 30% of revenue from 25% YoY, driven by new Novitium royalties
- R&D expense $71.7M included a $25M milestone charge for MSN license
- Cash and investments $1.05B as of Sept 30, 2026, up from $882.5M at Dec 31, 2025
- Reiterated full-year WAKIX net revenue guidance of $1.0B-$1.04B
- BP-205 MAD study showed favorable safety/tolerability; Phase 1b data expected Q1 2027
- Pitolisant GR NDA under FDA review, PDUFA date April 1, 2027
- CEO transition: Peter Anastasiou to succeed Jeffrey Dayno effective Jan 1, 2027
Financial Impact
EPS miss of ~45% vs consensus; revenue ~1.2% below consensus; operating income declined 17% YoY
Risk Factors
- AET ANDA litigation ruling expected Feb 2027 could threaten WAKIX exclusivity beyond March 2030
- Gross margin compression from new royalty obligations may persist
- CEO transition introduces execution risk despite planned continuity
- Pipeline milestones (BP-205, pitolisant GR, EPX-100) are years from commercialization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3395197 |
Track record
20 reports on HRMY
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +14.82% at T+20 after the Jul 16, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $33.21 Now $32.96 −0.75% settles Dec 15
- Nov 4, 202612d ago 8-K Bearish 5/10 No price data
- Nov 4, 202612d ago Press Release Bearish 5/10 Viewing Entry $34.42 Now $32.96 +4.23% settles Dec 3
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.02 Now $32.96 −10.97% settles Dec 2
- Oct 30, 202617d ago 8-K/A Neutral 3/10 Entry $37.91 Now $32.96 −13.06% settles Dec 1
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $38.50 Now $32.96 −14.39% settles Nov 25
- Oct 13, 20264w ago 8-K Neutral 3/10 Entry $37.03 to $33.55 Now $32.96 −10.99% ▼ −9.40% −5.79% vs SPY
- Oct 1, 20266w ago Press Release Neutral 3/10 Entry $39.57 to $38.59 Now $32.96 −16.70% ▼ −2.48% −3.18% vs SPY
- Aug 4, 202614w ago 8-K Bullish 7/10 No price data
- Aug 4, 202614w ago Press Release Bullish 6/10 Entry $38.78 Now $32.96 −15.01% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers